BioNTech's shares tumble—again—amid continued COVID vaccine sales slide
Fierce Pharma
MARCH 20, 2024
Sales came to 1.5 Four months ago, when BioNTech slashed its 2023 revenue projection from 5 billi | When BioNTech reported its fourth-quarter earnings Wednesday, it was another harsh reminder of the plummeting demand for COVID-19 vaccines. billion euros ($1.6 billion) for the fourth quarter and 3.8 billion euros ($4.1
Let's personalize your content